This study is exploring how a new medicine called PF-08052667 works for people with bladder cancer. Bladder cancer is a disease where cells in the bladder grow uncontrollably. The study is for adults with a type of bladder cancer that hasn't spread deep into the bladder muscles but may return or grow.
There are three parts to the study:
- Part 1 tests PF-08052667 alone with increasing doses.
- Part 2 tests PF-08052667 combined with Bacillus Calmette Guerin (BCG) and/or sasanlimab at fixed doses.
- Part 3 finds the best dose to use PF-08052667 alone or with BCG and/or sasanlimab.
PF-08052667 is given directly into the bladder (intravesical infusion) and sasanlimab is injected under the skin (subcutaneous injection). Participants can be in the study for up to 2 years, but it may end sooner if they choose to leave or for other reasons.
- Participation can last up to 2 years.
- All participants receive PF-08052667; some may also receive BCG and sasanlimab.
- No prior bladder radiation therapy is permitted.
How understandable was the trial content above?
Hard to understand
Easy to understand